Poziotinib is an investigational, orally administered, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 with exon 20 insertion mutations.
> To read the latest news about poziotinib, or to watch a video on its mechanism, click here.
Poziotinib is designed to be small and flexible.
Poziotinib is an investigational drug not approved by the FDA.
In pre-clinical models of cancer, poziotinib was shown to inhibit kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, leading to cancer cell death.
SPI-POZ-201 (Phase 2): HER2+ Metastatic Breast Cancer